BACKGROUND: The recently discovered plasma enzyme ADAMTS-13 cleaves the A2-domain of von Willebrand factor (VWF). A defective cleaving protease results in unusually large VWF multimers, which cause thrombotic thrombocytopenic purpura (TTP). AIM: Analysis of the ADAMTS-13 antigen levels in TTP patients compared with normal donors. METHODS: An antigen ELISA test was built, based on high affinity anti-ADAMTS-13 monoclonal antibodies, which were generated using genetic immunization. RESULTS: Specificity of the ADAMTS-13 antigen test was confirmed, as (i) plasma from a patient with acquired TTP but presenting without inhibitor did not contain antigen and (ii) the binding of recombinant ADAMTS-13 was inhibited by increasing amounts of normal plasma. The assay is sensitive as it can detect antigen levels as low as 1.6% of normal. The concentration in normal pooled human plasma was determined (1.03 +/- 0.15 microg mL(-1)) and arbitrarily set to 1 U mL(-1). The antigen levels in congenital TTP samples (34 +/- 21 mU mL(-1), n = 2), as well as in samples from patients with acquired TTP (231 +/- 287 mU mL(-1), n = 11), were clearly reduced when compared with normal Caucasian donors (951 +/- 206 mU mL(-1), n = 16). Remarkably, normal Chinese donors have a significantly lower antigen titer (601 +/- 129 mU mL(-1), n = 15), when compared with normal Caucasians. CONCLUSIONS: Our results show that acquired TTP patients suffer mainly from ADAMTS-13 antigen depletion, thereby indicating the importance of ADAMTS-13 antigen determination in diagnosis and patient follow-up.
BACKGROUND: The recently discovered plasma enzyme ADAMTS-13 cleaves the A2-domain of von Willebrand factor (VWF). A defective cleaving protease results in unusually large VWF multimers, which cause thrombotic thrombocytopenic purpura (TTP). AIM: Analysis of the ADAMTS-13 antigen levels in TTP patients compared with normal donors. METHODS: An antigen ELISA test was built, based on high affinity anti-ADAMTS-13 monoclonal antibodies, which were generated using genetic immunization. RESULTS: Specificity of the ADAMTS-13 antigen test was confirmed, as (i) plasma from a patient with acquired TTP but presenting without inhibitor did not contain antigen and (ii) the binding of recombinant ADAMTS-13 was inhibited by increasing amounts of normal plasma. The assay is sensitive as it can detect antigen levels as low as 1.6% of normal. The concentration in normal pooled human plasma was determined (1.03 +/- 0.15 microg mL(-1)) and arbitrarily set to 1 U mL(-1). The antigen levels in congenital TTP samples (34 +/- 21 mU mL(-1), n = 2), as well as in samples from patients with acquired TTP (231 +/- 287 mU mL(-1), n = 11), were clearly reduced when compared with normal Caucasian donors (951 +/- 206 mU mL(-1), n = 16). Remarkably, normal Chinese donors have a significantly lower antigen titer (601 +/- 129 mU mL(-1), n = 15), when compared with normal Caucasians. CONCLUSIONS: Our results show that acquired TTP patients suffer mainly from ADAMTS-13 antigen depletion, thereby indicating the importance of ADAMTS-13 antigen determination in diagnosis and patient follow-up.
Authors: Joshua Muia; Jian Zhu; Garima Gupta; Sandra L Haberichter; Kenneth D Friedman; Hendrik B Feys; Louis Deforche; Karen Vanhoorelbeke; Lisa A Westfield; Robyn Roth; Niraj Harish Tolia; John E Heuser; J Evan Sadler Journal: Proc Natl Acad Sci U S A Date: 2014-12-15 Impact factor: 11.205
Authors: Karen De Ceunynck; Susana Rocha; Simon F De Meyer; J Evan Sadler; Hiroshi Uji-i; Hans Deckmyn; Johan Hofkens; Karen Vanhoorelbeke Journal: J Biol Chem Date: 2014-02-18 Impact factor: 5.157
Authors: L Deforche; E Roose; A Vandenbulcke; N Vandeputte; H B Feys; T A Springer; L Z Mi; J Muia; J E Sadler; K Soejima; H Rottensteiner; H Deckmyn; S F De Meyer; K Vanhoorelbeke Journal: J Thromb Haemost Date: 2015-10-20 Impact factor: 5.824
Authors: Wouter Pos; Nicoletta Sorvillo; Rob Fijnheer; Hendrik B Feys; Paul H P Kaijen; Gestur Vidarsson; Jan Voorberg Journal: Haematologica Date: 2011-06-28 Impact factor: 9.941
Authors: J Muia; W Gao; S L Haberichter; L Dolatshahi; J Zhu; L A Westfield; S C Covill; K D Friedman; J E Sadler Journal: J Thromb Haemost Date: 2013-08 Impact factor: 5.824